Reducing variation in the treatment of men with high-risk/locally advanced prostate cancer
Thursday 16th December 2021
9am – 11am, online via Zoom
Session 1
Chair: Noel Clarke, NPCA Uro-Oncological Clinical Lead
| Impact of the Covid-19 pandemic: findings from the National Prostate Cancer Audit |
Julie Nossiter NPCA Audit Lead, RCS/ Assistant Professor, LSHTM |
Watch the video Download the slides |
| Update on NHS England’s Data and Action Plan |
Peter Johnson National Clinical Director for Cancer, NHS England/ Professor of Medical Oncology, University Hospital, Southampton
|
Watch the video Download the slides |
Session 2
Chair: Heather Payne, NPCA Oncological Clinical Lead
| Determinants of variation in radical local treatment for men with high-risk localised or locally advanced prostate cancer in England |
Matt Parry NPCA Clinical Fellow/ Urology Registrar |
Watch the video Download the slides |
| Optimising the management of patients with high risk/locally advanced disease – improving the outcomes of older men |
Danielle Harari Geriatric-oncology Consultant and Clinical Lead, Geriatric Oncology liaison Development Team, Guy’s and St. Thomas’ Presented by Ajay Aggarwal, NPCA Oncology Coordinator/ Consultant Clinical Oncologist at Guy’s and St Thomas’ NHS Trust and Associate Professor, LSHTM |
Watch the video Download the slides |
| How do we reduce variation in access to treatment for all men? The experience of black and ethnic minority groups |
Jonathan Makanjuola Consultant Urological Surgeon, King’s College Hospital
|
Watch the video Download the slides |
Last updated: 31 January 2022, 3:56pm